NASDAQ:CLOV 24 October 2025 - 11 June 2026

Clover Health Investments, Corp. shares are up as the company finally got clarity on a key question hanging over its 2027 forecast: would its main Medicare Advantage plan land at 3.5 or 4.5 stars? Investors got an answer this week. On June 10, Clover said in a Form 8-K that CMS bumped the 2026 Star Rating for Contract H5141, its PPO plan, to 4.5 stars. The move follows a federal judge tossing the earlier 3.5-star rating.

Stock Performance: Clover Health stock has been exceptionally volatile in mid‑October 2025. On Oct. 21 it jumped ~8.7% intraday to ~$3.20 Marketbeat, and on Oct. 24 it spiked another ~18%, trading near $3.79 Reuters. According to Reuters data, that surge propelled CLOV close to its 52-week high and far above its recent 50‑day moving average Marketbeat. The 200-day average was also eclipsed, signaling strong upward momentum Marketbeat. This rally has come on unusually heavy volume Reuters, reflecting frenzied buying. By contrast, the stock was languishing near multi-year lows just a few months ago, underscoring the swing. Overall, CLOV’s high beta and large short interest mean it tends to move sharply on news and market sentiment Marketbeat Fintel.